Recent Blog Posts
-
Facebook Faces Short Wall Street Honeymoon
May 21 201210:54 am EDT -
Who Loses From Tepid Facebook Offering?
May 18 20122:57 pm EDT -
Rich VCs Get Richer
May 18 201210:25 am EDT -
Hey, Facebook: No Pop for You
May 18 20128:29 am EDT -
Facebook IPO Is On
May 17 20125:12 pm EDT -
A $1.5B Valuation Sticks on Pinterest
May 17 20129:49 am EDT -
Facebook IPO Size Balloons—Again
May 16 20129:52 am EDT -
Facebook Wants Into the 12-Figure Club
May 15 20129:37 am EDT -
Do You Have a Praiseworthy Credit Card?
May 14 20121:06 pm EDT -
New Breed of Company Buyers Emerge
May 14 201210:42 am EDT
Cash Comes to Cleantech
Peter Thiel and other critics of cleantech investing have to be shaking their heads.
Not only did Vinod Khosla, famous for his commitment to investing in renewable energy, raise one of the largest venture funds of 2011 in part to invest in cleantech, it looks like still more money is going toward the field.
Flagship Ventures of Cambridge, Massachusetts, has pulled together a new $270 million fund to invest in healthcare and cleantech. And Sunnyvale, California, solar firm AQT Solar has raised $18.7 million of a planned $22 million funding round.
The argument put forward by Thiel, a PayPal founder and now investor, and others against such investing is that cleantech companies are too dependent on government policy to be good bets for investors. Also, critics have argued, cleantech and biotech companies both tend to take a lot of money and time to mature into businesses with a chance to go public or be bought.
But Flagship managing partner Noubar Afeyan told Scott Kirshner of the Boston Globe that there’s still money to be made investing in renewable energy, for instance. It just takes more patience than investing in the latest technology fad.
"I don't think the level of activity has gone down,” he said. “I think that the level of noise has gone down. There was a time in cleantech when people were just spraying money around indiscriminately. What we've seen is that cleantech has turned out to be more like biotech. You need patient, flexible execution to generate reasonable companies."
Kent Bernhard Jr. is News Editor of Portfolio.com
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.





